Auris Medical Holding

US: EARS

$13.5m market cap

$0.36 last close

Auris Medical is a Swiss biopharmaceutical company developing neurotology therapeutics. The company is developing intranasal betahistine in a Phase I trial for mental disorder supportive care and is entering Phase II for vertigo; both are designed to demonstrate proof-of-concept.

Investment summary

Auris Medical is a clinical-stage biopharmaceutical company developing pharmacotherapies for neurologic disorders of the inner ear. The company’s primary focus is on the development of AM-125 (intranasal betahistine) for the treatment of acute vertigo. Oral betahistine dihydrochloride has been prescribed in Europe for decades for all types of vertigo, with an average 26% market share but is not available in the US. Following positive Phase I data where their formulation demonstrated superior bioavailability to the oral version, Auris expects to initiate its Phase II clinical trial in 138 patients with surgically-induced acute vertigo in Q119. Auris is also developing AM-201, an intranasal betahistine formulation, for co-administration with olanzapine to counteract adverse effects, especially weight gain.

Y/E Dec
Revenue (CHFm)
EBITDA (CHFm)
PBT (CHFm)
EPS (CHFc)
P/E (x)
P/CF (x)
2016A 0.0 (30.3) (31.0) (89.87) N/A N/A
2017A 0.0 (24.5) (25.9) (53.60) N/A N/A
2018E 0.0 (11.7) (12.7) (41.58) N/A N/A
2019E 0.0 (11.4) (11.8) (30.78) N/A N/A
Last updated on 21/02/2019
Industry outlook

Acute vertigo/dizziness is one of the most common causes of visits to the emergency room with roughly 2.6m visits associated with the condition each year.

Last updated on 21/02/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (CHFm) 5.6
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (11.7) (40.2) (86.4)
Relative* (15.0) (42.9) (86.7)
52-week high/low US$3.2/US$0.2
*% relative to local index
Key management
Thomas Meyer CEO
Hernan Levett CFO